Abbott Spinoff

· TGI - Intelligence
Authors

The drug and medical device company of Abbott plans to spin off its pharmaceutical business into a separate company by the end of 2012. The new company, named AbbVie, will focus solely on branded drugs, including the blockbuster anti-inflammatory drug Humira.

The split is meant to free the North Chicago, Ill., company from the risks and obligations of developing innovative pharmaceutical drugs, leaving it with a more predictable business built around nutritional formula, generic drugs and heart stents.

Holford predicted that AbbVie shares would be worth about $55 after the split, and he valued the remaining Abbott business at $30 per share. The company is his top pick for the rest of the year, and its shares could rise on data from clinical trials and other events, he said.

source

dddmag

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: